Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination. (1st December 2016)

• Record Type: Journal Article
• Authors: Li, Fenge; Chen, Caixia; Ju, Tao; Gao, Junqin; Yan, Jun; Wang, Peng; Xu, Qiang; Hwu, Patrick; Du, Xueming; Lizée, Gregory
• Is Part Of: Oncoimmunology. Volume 5:Number 12(2016)
• Publication Date: 2016-12-01
• Subjects: Cancer vaccine -- cytotoxic T cells -- EGFR L858R mutation -- epidermal growth factor receptor -- lung cancer -- neo-epitope -- personalized immunotherapy; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2016.1238539
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Personalized immunotherapy targeting tumor-specific mutations represents a highly promising approach to cancer treatment. Here, we describe an Asian lung squamous cell carcinoma patient demonstrating frank disease progression following chemotherapy and EGFR inhibitor treatment. Based on tumor mutational profiling and HLA typing, a saline-based multi-epitope peptide vaccine was designed and administered along with topical imiquimod as an adjuvant. Weekly neo-epitope peptide vaccination was followed by a rapid and dramatic regression of multiple lung tumor nodules, while a much larger liver metastasis remained refractory to treatment. Peripheral blood immune monitoring showed that specific cytotoxic T lymphocytes (CTLs) were induced primarily against peptide targets encompassing the widely shared EGFR L858R mutation, particularly one restricted to HLA-A*3101. Immunological targeting of this driver mutation may be of particular benefit to Asian lung cancer patients due to its relatively high prevalence within this patient population.